
    
      Phase IV, Single-Arm, Open-Label Study Evaluating Bone Mineral Density in HIV-1-Infected
      Adults â‰¥50 Years Old Switching from EVG/COBI/FTC/TAF (Genvoya) or EVG/COBI/FTC/TDF (Stribild)
      to ABC/DTG/3TC (Triumeq)

      To evaluate the impact on BMD, as measured by DEXA over 48 weeks, of switching from an
      INSTI-based regimen with either TDF or TAF to a regimen of ABC/DTG/3TC (administered as
      commercial Triumeq) in chronic HIV-infected patients over the age of 50
    
  